StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research note published on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.
Separately, HC Wainwright decreased their target price on shares of CASI Pharmaceuticals from $12.00 to $6.00 and set a buy rating on the stock in a research note on Wednesday, May 15th.
Read Our Latest Research Report on CASI
CASI Pharmaceuticals Stock Performance
CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.66). The firm had revenue of $3.41 million during the quarter. CASI Pharmaceuticals had a negative net margin of 105.76% and a negative return on equity of 110.11%. As a group, research analysts predict that CASI Pharmaceuticals will post -2.56 EPS for the current fiscal year.
Institutional Trading of CASI Pharmaceuticals
An institutional investor recently bought a new position in CASI Pharmaceuticals stock. Howland Capital Management LLC purchased a new position in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 40,429 shares of the biotechnology company’s stock, valued at approximately $146,000. Howland Capital Management LLC owned 0.30% of CASI Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 22.23% of the stock is currently owned by institutional investors.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
Further Reading
- Five stocks we like better than CASI Pharmaceuticals
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Survey: Top 175 Fittest Retirement Locations in America
- How to Calculate Inflation Rate
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Best Aerospace Stocks Investing
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.